Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis

Soloway, 1972, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis, Gastroenterology, 63, 820, 10.1016/S0016-5085(19)33223-8 Czaja, 1991, Autoimmune Liver Disease, 143 Czaja, 1999, Drug therapy in the management of type 1 autoimmune hepatitis, Drugs, 57, 49, 10.2165/00003495-199957010-00005 Davis, 1984, Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis, Gastroenterology, 87, 1222, 10.1016/0016-5085(84)90186-0 Roberts, 1996, Prognosis of histological cirrhosis in type 1 autoimmune hepatitis, Gastroenterology, 110, 848, 10.1053/gast.1996.v110.pm8608895 Czaja, 1980, Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission, Gastroenterology, 78, 518, 10.1016/0016-5085(80)90866-5 Hegarty, 1983, Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis, Hepatology, 3, 685, 10.1002/hep.1840030510 Czaja, 1981, Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis, N Engl J Med, 304, 5, 10.1056/NEJM198101013040102 Czaja, 1987, Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis, Gastroenterology, 92, 215, 10.1016/0016-5085(87)90862-6 Czaja, 1981, Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features, Gastroenterology, 80, 687, 10.1016/0016-5085(81)90126-8 Czaja, 1984, Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis, Hepatology, 4, 622, 10.1002/hep.1840040409 Czaja, 1990, Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis, Hepatology, 11, 1044, 10.1002/hep.1840110621 Stellon, 1988, Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal, Hepatology, 8, 781, 10.1002/hep.1840080414 Johnson, 1995, Azathioprine for long-term maintenance of remission in autoimmune hepatitis, N Engl J Med, 333, 958, 10.1056/NEJM199510123331502 Czaja, 1993, Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses, J Hepatol, 17, 180, 10.1016/S0168-8278(05)80035-2 Czaja, 1999, Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial, Hepatology, 30, 1381, 10.1002/hep.510300603 Czaja, 2000, Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis, Gastroenterology, 119, 1312, 10.1053/gast.2000.0010000001 Richardson, 2000, Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine, J Hepatol, 33, 371, 10.1016/S0168-8278(00)80271-8 Mistilis, 1968, Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival, Australas Ann Med, 17, 214, 10.1111/imj.1968.17.3.214 Johnson, 1993, Meeting report. International Autoimmune Hepatitis Group, Hepatology, 18, 998, 10.1002/hep.1840180435 Alvarez, 1999, International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis, J Hepatol, 31, 929, 10.1016/S0168-8278(99)80297-9 Czaja, 1995, The validity and importance of subtypes of autoimmune hepatitis: a point of view, Am J Gastroenterol, 90, 1206 Czaja, 1983, Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology, Gastroenterology, 85, 713, 10.1016/0016-5085(83)90030-6 Czaja, 1996, Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis, Hepatology, 24, 1068, 10.1002/hep.510240515 Czaja, 1997, Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis, Dig Dis Sci, 42, 1688, 10.1023/A:1018809431189 Homburger, 1998, Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods, Arch Pathol Lab Med, 122, 993 Czaja, 1992, Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis, Gastroenterology, 103, 1290, 10.1016/0016-5085(92)91518-9 Summerskill, 1975, Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared, Gut, 16, 876, 10.1136/gut.16.11.876 Ishak, 1995, Histological grading and staging of chronic hepatitis, J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 Czaja, 1993, Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis, Gastroenterology, 105, 1824, 10.1016/0016-5085(93)91081-R 2002, Pathology of the Liver, 415 Czaja, 1993, Significance of HLA DR4 in type 1 autoimmune hepatitis, Gastroenterology, 105, 1502, 10.1016/0016-5085(93)90157-8 Czaja, 1997, Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis, Hepatology, 25, 317, 10.1002/hep.510250211 Villanueva, 1990, Changes in the expression of HLA class II antigens on peripheral blood monocytes from aged humans, Dis Markers, 8, 85 Murasko, 1990, T cell function in aging: mechanisms of decline, Ann Rev Gerontol Geriatr, 10, 71 Currie, 1992, Immunosenescence, Compr Ther, 18, 26 Ward, 1990, Age-associated clinical manifestations of systemic lupus erythematosus: a multivariate regression analysis, J Rheum, 17, 476 Talor, 1991, Hypothesis: the aging paradox and autoimmune disease, Autoimmunity, 8, 245, 10.3109/08916939108997112